Aarti Drugs Share Price

NSE: AARTIDRUGS

₹ 408.00

-₹2.00 (-0.49%)

Last updated 24 Jul, 2026, 15:29 IST

Aarti Drugs Share Price Today

As of 25 Jul 2026, Aarti Drugs share price is ₹408.00. The stock opened at ₹409.00, compared to its previous close of ₹410.00. During today's trading session, Aarti Drugs share price moved in the range of ₹401.00 to ₹410.00, with an average price of ₹405.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹318.95 and a high of ₹549.30. On the performance front, Aarti Drugs share price has increased by 9.31% over the last six months and is down 24.90% on a year-on-year basis.

₹401.00

0.49% down today

₹410.00

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 142.45% QoQ

Latest Earning

Net Profit TrendUp by 36.28% QoQ

Latest Earning

Revenue TrendUp by 19.59% QoQ

Stock Performance

OutperformingBeat Nifty by 9.67 % in last 1 month

Shareholding Pattern

PromoterPromoter decreased stake by 1.08%

Shareholding Pattern

DIIDII increased stake by 158.10%

Shareholding Pattern

FIIFII decreased stake by 3.36%

Aarti Drugs Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹3,76,104-₹1,23,896 (-24.78%)

3 Year

₹3,40,145-₹1,59,855 (-31.97%)

5 Year

₹3,03,042-₹1,96,958 (-39.39%)

₹323.60₹485.40

Circuit Low

Circuit High

₹318.95₹549.30

52-Week Low

52-Week High

Circuit

₹323.60

₹485.40

52-week

₹318.95

₹549.30

Mkt Cap Cr

3,693.24

P/E

19.14

P/B

2.41

ROE

12.58%

D/E

0.30

ROCE

11.51%

Div. Yield

0.49%

EPS(TTM)

18.54

Turnover

1.35

EV/EBITDA

13.89

Net Margin

0.00%

Op. Margin

0.00%

ROA

6.92%

Quick Ratio

0.00

Curr. Ratio

2.56

Mkt Cap Cr

3,693.24

P/E

19.14

P/B

2.41

ROE

12.58%

D/E

0.30

ROCE

11.51%

Div. Yield

0.49%

EPS(TTM)

18.54

Turnover

1.35

EV/EBITDA

13.89

Net Margin

0.00%

Op. Margin

0.00%

ROA

6.92%

Quick Ratio

0.00

Curr. Ratio

2.56

Based on fundamentals, this stock's

Performance

Excellent

Aarti Drugs outperforming all market indices

Valuation

Fairly Valued

Aarti Drugs appears to be fairly valued compared to its peers

Earnings

Excellent

Aarti Drugs revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,03,472.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	96,204.70	30.22	2.53	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.40	16.70%	97.21	0.12%	0.64	13.72

Aarti Drugs Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹2,387.03	₹2,528.58	₹2,716.05	₹2,488.65
Other Income	₹16.36	₹4.03	₹2.19	₹11.32
Total Revenue	₹2,403.39	₹2,532.61	₹2,718.25	₹2,499.96
Total Expenses	₹2,191.62	₹2,297.08	₹2,494.07	₹2,230.01
Profit Before Tax	₹211.77	₹235.53	₹224.18	₹269.96
Tax	₹43.67	₹63.94	₹57.82	₹64.96
Profit After Tax	₹168.10	₹171.59	₹166.36	₹205.00
EPS - Basic	₹18.42	₹18.65	₹17.97	₹22.12
EPS - Diluted	₹18.42	₹18.65	₹17.97	₹22.12

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	₹211.77	₹235.53	₹224.18	₹269.96
Income before WC changes	₹296.11	₹318.54	₹309.33	₹341.14
Change in Assets	₹47.31	₹195.32	-₹88.60	-₹304.50
Change in Liabilities	-₹43.73	-₹92.53	-₹27.74	₹117.15
Change in WC	₹3.59	₹102.79	-₹116.34	-₹187.35
Cash flow from Operations	₹244.58	₹358.92	₹133.32	₹70.41
Cash flow from Investing	-₹164.63	-₹223.65	-₹163.97	-₹149.64
Cash flow from Financing	-₹82.12	-₹136.03	₹16.54	₹92.03
Total Cash Flow	-₹2.17	-₹0.76	-₹14.11	₹12.80
Cash (Start of the year)	₹6.74	₹7.50	₹21.61	₹8.81
Cash (End of the year)	₹4.58	₹6.74	₹7.50	₹21.61

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹1,236.32	₹1,111.64	₹929.05	₹814.59
Current Assets	₹1,338.36	₹1,320.72	₹1,492.35	₹1,393.37
Total Assets	₹2,574.68	₹2,432.36	₹2,421.40	₹2,207.96
Current Liabilities	₹836.97	₹795.54	₹932.98	₹940.06
Net Current Asset	₹501.39	₹525.18	₹559.37	₹453.31
Non-Current Liabilities	₹368.37	₹354.86	₹295.75	₹231.60
Equity Capital	₹1,369.34	₹1,281.95	₹1,192.67	₹1,036.30
Total Equity & Liabilities	₹2,574.68	₹2,432.36	₹2,421.40	₹2,207.96

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹2,173.65	₹2,266.91	₹2,497.97	₹2,251.17
Other Income	₹13.57	₹4.18	₹2.23	₹4.77
Total Revenue	₹2,187.23	₹2,271.09	₹2,500.20	₹2,255.95
Total Expenses	₹1,988.47	₹2,078.61	₹2,295.39	₹2,000.45
Profit Before Tax	₹198.75	₹192.48	₹204.81	₹255.50
Tax	₹41.44	₹50.60	₹52.00	₹60.50
Profit After Tax	₹157.31	₹141.88	₹152.81	₹195.00
EPS - Basic	₹17.24	₹15.43	₹16.50	₹21.04
EPS - Diluted	₹17.24	₹15.43	₹16.50	₹21.04

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	₹198.75	₹192.48	₹204.81	₹255.50
Income before WC changes	₹268.84	₹270.17	₹283.24	₹322.26
Change in Assets	₹9.12	₹168.24	-₹76.31	-₹315.17
Change in Liabilities	-₹5.92	-₹50.08	₹9.60	₹112.91
Change in WC	₹3.19	₹118.17	-₹66.71	-₹202.27
Cash flow from Operations	₹220.08	₹337.10	₹161.70	₹39.90
Cash flow from Investing	-₹134.92	-₹187.09	-₹131.14	-₹125.36
Cash flow from Financing	-₹84.60	-₹148.81	-₹30.54	₹84.11
Total Cash Flow	₹0.56	₹1.20	₹0.03	-₹1.35
Cash (Start of the year)	₹2.72	₹1.52	₹1.49	₹2.84
Cash (End of the year)	₹3.28	₹2.72	₹1.52	₹1.49

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹1,092.23	₹990.60	₹845.96	₹761.33
Current Assets	₹1,180.56	₹1,181.02	₹1,349.53	₹1,273.19
Total Assets	₹2,272.79	₹2,171.62	₹2,195.50	₹2,034.52
Current Liabilities	₹705.79	₹684.60	₹847.39	₹854.68
Net Current Asset	₹474.77	₹496.42	₹502.14	₹418.52
Non-Current Liabilities	₹315.65	₹311.81	₹233.80	₹207.67
Equity Capital	₹1,251.35	₹1,175.21	₹1,114.30	₹972.17
Total Equity & Liabilities	₹2,272.79	₹2,171.62	₹2,195.50	₹2,034.52

* All values are in INR Crore

Qty

Bid

350

404.5

Ask

Qty

Bid Total: 350

Ask Total: 0

Buy orders: 100%

Sell orders: 0%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Neutral

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

58.68

Neutral

ATR (14)

15.24

Neutral

STOCH(9,6)

41.62

Neutral

STOCH RSI (14)

25.03

Neutral

ADX(9)

44.21

Bearish

UO(9)

48.41

Neutral

ROC(12)

5.41

Bullish

WillR(14)

-43.76

Neutral

Period

Simple value

Exponential vaue

417.84

414.56

10D

412.89

410.84

20D

397.53

401.82

50D

384.63

388.99

100D

372.69

385.6

About Aarti Drugs

ISIN

INE767A01016

Sector Market Cap

₹ 3,693.24 Cr

Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals include benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.

Aarti Drugs Financial Highlights

Revenue: Aarti Drugs reported revenue of ₹2,567.70 crore in FY26 vs ₹2,403.39 crore in FY25. It showed an increase of 6.84% on a yearly basis.
Operating Profit: Aarti Drugs reported an operating profit of ₹210.90 crore in FY26 vs ₹211.77 crore in FY25. It showed a decrease of 0.41% on a year-on-year basis.
Net Profit: Aarti Drugs reported a net profit of ₹194.94 crore in FY26 vs ₹168.10 crore in FY25. It showed an increase of 15.97% on a yearly basis.

Aarti Drugs Quarterly Result Highlights

Aarti Drugs reported revenue of ₹721.06 crore in Mar 2026, compared with ₹602.94 crore in Dec 2025, representing an increase of 19.59% on a quarter-on-quarter (QoQ) basis.
Aarti Drugs reported an operating profit of ₹70.36 crore in Mar 2026, compared with ₹29.02 crore in Dec 2025, representing an increase of 142.45% on a quarter-on-quarter (QoQ) basis.
Aarti Drugs reported a profit of ₹55.26 crore in Mar 2026, compared with ₹40.55 crore in Dec 2025, reflecting an increase of 36.28% on a QoQ basis.
The earnings per share (EPS) of Aarti Drugs stood at ₹18.42 during Mar 2026.